Gliptapil 50mg Tablet contains Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Vildagliptin enhances the incretin system by inhibiting the DPP-4 enzyme, thereby increasing the levels of active incretin hormones such as GLP-1 and GIP. This action results in improved glucose-dependent insulin secretion and decreased glucagon release, leading to better glycemic control. Gliptapil is typically prescribed as monotherapy or in combination with other antidiabetic agents, including metformin, when diet and exercise alone are insufficient to achieve target blood glucose levels. The recommended dose is 50mg once or twice daily, depending on the clinical scenario and patient response. Gliptapil is generally well tolerated, with a low risk of hypoglycemia when used as monotherapy. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to Vildagliptin. Caution is advised in patients with hepatic or renal impairment, and periodic monitoring of liver enzymes is recommended. Gliptapil offers an effective and convenient option for improving glycemic control in adults with type 2 diabetes mellitus.